Unicycive Therapeutics to Participate in Upcoming Investor Events in September

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 9/4/2026

1. ZS
2. LULU
3. IOT
4. SPY
5. PATH

6. DOCU
7. ASAN
8. NVDA
9. GWRE
10. CIEN

Get Alerts UNCY Hot Sheet

Price: $5.16 -2.64%

Overall Analyst Rating:
SELL (= Flat)

EPS Growth %: +23.9%

Join SI Premium – FREE

LOS ALTOS, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in two investor events in September.

Event: H.C. Wainwright 27th Annual Global Investment Conference
Type: Fireside chat
Date/Time: Wednesday, September 10, 2025, at 8:30 a.m. ET

Event: Truist Securities Virtual Fireside Chat
Date/Time: Wednesday, September 17, 2025, at 10 a.m. ET

A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. To schedule a 1x1 meeting with management, please contact your conference representative.

About Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.

Investor Contact:

Kevin Gardner
LifeSci Advisors
[email protected]

Media Contact:
Rachel Visi
Real Chemistry
[email protected]

SOURCE: Unicycive Therapeutics, Inc.